Cleancard vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
US YC S23 at-home 30-minute cancer screening for prostate, bladder, and ovarian cancers; $846K Mayo Clinic/TQ Ventures/YC-backed with synthetic biology + computer vision from Oxford Rhodes Scholar founders competing with GRAIL for accessible early...
About
Cleancard is a United States-based at-home cancer screening company — backed by Y Combinator (S23) with $846,000 in total funding from Mayo Clinic Platform, TQ Ventures, Urban Innovation Fund, Y Combinator, and the Creative Destruction Lab — developing a 30-minute at-home diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers from a single patient sample for prostate, bladder, and ovarian cancers. Founded by Luca Springer and Thomas Carroll (both Rhodes Scholars from Oxford), Cleancard targets the massive unmet need for accessible, affordable cancer screening outside of clinical settings — the 30-minute result time and home-based format enabling screening at the frequency and convenience required for early cancer detection programs.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.